Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0780 in combination with lipid-lowering therapies for elevated LDL-C
NCT06742853Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of laroprovstat in hypercholesterolemia (6 arms), sponsored by AstraZeneca. Primary endpoints: Low-density Lipoprotein Cholesterol (direct) at 4 weeks and Adverse Events at 14 weeks. Started Dec 2024; status: completed.
02
Drugs
laroprovstat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06742853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742853.